Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma

Melanoma Research

Volumn 7, Issue 5, 1997, Pages 417-419

  Pontes, L ^a   Lopes, M ^a   Ribeiro, M ^a   Santos, J G ^a   Azevedo, M C ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

Dacarbazine; Fotemustine; Isolated limb perfusion; Melanoma

Indexed keywords

DACARBAZINE; FOTEMUSTINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMB PERFUSION; MALE; MELANOMA; PRIORITY JOURNAL; TUMOR LOCALIZATION;

EID: 0030725992     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199710000-00008     Document Type: Article

References (13)

1. Lejeune FJ, Lienard D, Douaihy M, Vadoud Seyedi J, Ewaalenko P. Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 1989; 15: 510-519.
2. Coit DG. Isolation limb perfusion for melanoma: current trends and future directions. Melanoma Res 1994; 4 (suppl 1): 57-60.
3. Lienard D, Eggermont AM, Koops HS, Lejeune FJ. High dose rTNF-α, rIFN-γ, and melphalan in isolation perfusion produces 90% CR in melanoma in transit metastases. Melanoma Res 1993; 3(suppl 1): 30.
4. Wieberdink J, Benckhuisen C, Braat RP, Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
5. Mohr P, Weichental M, Abenhoff J, Stephan U, Breitbart EW. Long-term complete remission in patients with metastatic malignant melanoma treated by fotemustine (FTMU). J Cancer Res Clin Oncol 1994; 120(suppl): R153.
6. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-1360.
7. Gerard B, Aamdal S, Lee SM, Leyras S, Lucas C, d'Incalci M, Bizarri JP. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine in patients with melanoma. Eur J Cancer 1993; 29A(5): 711-719.
8. Olivier V, Aliaga A, Lopez Lopez JJ, Perez E, Ponchon A, Bizarri JP, Cour V. Long-term complete remissions in patients with malignant melanoma treated by fotemustine and dacarbazine. Ann Oncol 1992; 3(suppl 5): 614.
9. 6 alkylguanine DNA alkyltransferase. Cancer Res 1988; 48: 1521-1527.
10. Zlotogorski C, Erickson LC. Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis 1983; 4(6): 759-763.
11. 6 alkylguanine DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. Biochem Pharmacol 1989; 38(6): 929-934.
12. 6 alkylguanine DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51: 614-623.
13. Krementz ET. Regional perfusion: current sophistication, what next? Cancer 1986; 37: 416-432.